Loading…
Spruce Biosciences, Inc. is projected to rise to $52.49 by 2027, a +23% move from its current price of $42.83. SPRB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $41.41 | $42.86 | $44.37 | +0.08% |
| Aug 5 | $40.85 | $42.90 | $45.05 | +0.16% |
| Aug 6 | $40.43 | $42.93 | $45.59 | +0.24% |
| Aug 7 | $40.09 | $42.97 | $46.05 | +0.32% |
| Aug 8 | $39.80 | $43.00 | $46.46 | +0.40% |
| Aug 9 | $39.54 | $43.03 | $46.84 | +0.48% |
| Aug 10 | $39.30 | $43.07 | $47.20 | +0.56% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $39.30 | $43.07 | $47.20 | +0.56% |
| Week 2 | $38.05 | $43.31 | $49.30 | +1.12% |
| Week 3 | $37.16 | $43.55 | $51.04 | +1.68% |
| Week 4 | $36.46 | $43.79 | $52.60 | +2.25% |
| Week 5 | $35.88 | $44.04 | $54.05 | +2.82% |
| Week 6 | $35.38 | $44.29 | $55.43 | +3.40% |
| Week 7 | $34.95 | $44.53 | $56.75 | +3.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B.
It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns.
In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. Spruce Biosciences has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds, and it has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd.
to develop, manufacture, and commercialize Tildacerfont for CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Spruce Biosciences, Inc. (SPRB) operates in the Healthcare sector as a biopharmaceutical company. The current price is $41.99 with a market cap of $115.57M, and the company is ranked #3954 by market capitalization.
The near-term outlook shows a neutral to modestly bullish path in the forecast, with 2026 showing a neutral sentiment and a 2026 average of $41.99 and a high of $55.89. The 30-day range trades between $33.42 and $52.76, with a resistance at $55.88 and support at $41.99.
From 2027 onward, the forecast envisions a bullish trajectory, as the average price climbs from $51.48 in 2027 to $57.59 in 2028 and $54.08 in 2029, culminating in a long-run average of $137.48 by 2050. The maximum forecast extends to $279.42 in 2050, indicating substantial upside potential over the long term.
A major floor 24.6% below — a decisive break under it would weaken the trend.
The nearest floor, 3.2% below — buyers have tended to step in here.
The nearest ceiling, 30.5% above — a clean break opens room to run.
A major ceiling 64.6% above — clearing it would confirm fresh momentum.
Key SPRB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SPRB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $42.25 | Buy | $42.78 | Buy |
| MA 10 | $43.41 | Sell | $43.54 | Sell |
| MA 20 | $45.82 | Sell | $45.38 | Sell |
| MA 50 | $49.04 | Sell | $49.24 | Sell |
| MA 100 | $54.85 | Sell | $60.01 | Sell |
| MA 200 | $72.73 | Sell | $203.69 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.46 | Neutral |
| Stoch RSI (14) | 77.85 | Neutral |
| CCI (20) | -70.45 | Neutral |
| Williams %R (14) | -71.89 | Info |
| MACD (12,26,9) | -0.16 | Sell |
| ROC (12) | -5.74 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 28.11 | Neutral |
| TRIX (15) | -0.63 | Sell |
| Awesome (5,34) | -6.22 | Sell |
| Ultimate (7,14,28) | 34.00 | Neutral |
| Momentum (10) | -0.71 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 41.89 | Buy |
| ADX (14) | 21.03 | Sell |
| ATR (14) | 1.20 | Info |
The 30-day technical picture is BEARISH, with RSI14 at 30, suggesting restrained near-term momentum. The stock is trading below the 50-day simple moving average of $50.20 and well below the 200-day simple moving average of $75.92, indicating potential overhead resistance.
Current price sits at the support level of $41.99, with resistance at $55.88. The 30-day range has fluctuated between $33.42 and $52.76, highlighting a near-term trading band and modest upside potential should resistance be overcome.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $41.45 | $42.83 | $56.79 | 0% | Neutral | |
| $40.85 | $52.49 | $71.90 | +23% | Bullish | |
| $44.50 | $59.33 | $85.09 | +39% | Bullish | |
| $40.15 | $55.20 | $82.03 | +29% | Bullish | |
| $37.79 | $53.38 | $81.72 | +25% | Bullish | |
| $36.71 | $53.18 | $83.52 | +24% | Bullish | |
| $36.67 | $54.36 | $87.36 | +27% | Bullish | |
| $47.12 | $71.42 | $117.16 | +67% | Bullish | |
| $47.35 | $73.29 | $122.53 | +71% | Bullish | |
| $42.45 | $67.05 | $114.08 | +57% | Bullish | |
| $55.50 | $96.20 | $176.05 | +125% | Bullish | |
| $69.99 | $143.26 | $291.11 | +234% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $41.45 | $42.83 | $51.16 | +0.00% |
| September 2026 | $36.95 | $44.04 | $54.20 | +2.82% |
| October 2026 | $38.30 | $46.05 | $57.45 | +4.58% |
| November 2026 | $37.27 | $45.13 | $56.91 | -2.00% |
| December 2026 | $36.59 | $44.60 | $56.79 | -1.17% |
Click any year to see its month-by-month SPRB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SPRB price prediction for 2026 points to an average of $42.83 (low $41.45, high $56.79) — a potential gain of 0% on today's $42.83. Price action looks broadly range-bound.
In 2027, SPRB is projected to trade between $40.85 and $71.90, averaging $52.49 — a potential gain of +23% from today's $42.83. That is up +23% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Spruce Biosciences, Inc.'s 2028 outlook centres on $59.33, within a $44.50 to $85.09 range. That is up +13% on the projected 2027 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2029, SPRB could reach as high as $82.03, with a base case around $55.20 and support toward $40.15 — roughly +29% from $42.83. Buyers look set to stay in control over this stretch.
Expect SPRB to range from $37.79 to $81.72 through 2030. The $53.38 average target implies a +25% move from current prices. That is -3% versus the projected 2029 average. Momentum favours further upside here.
The SPRB price prediction for 2031 points to an average of $53.18 (low $36.71, high $83.52) — a potential gain of +24% on today's $42.83. Buyers look set to stay in control over this stretch.
In 2032, SPRB is projected to trade between $36.67 and $87.36, averaging $54.36 — a potential gain of +27% from today's $42.83. That is up +2% on the projected 2031 average. Momentum favours further upside here.
Spruce Biosciences, Inc.'s 2033 outlook centres on $71.42, within a $47.12 to $117.16 range. That is up +31% on the projected 2032 average. That marks a +67% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, SPRB could reach as high as $122.53, with a base case around $73.29 and support toward $47.35 — roughly +71% from $42.83. Momentum favours further upside here.
Expect SPRB to range from $42.45 to $114.08 through 2035. The $67.05 average target implies a +57% move from current prices. That is -9% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The SPRB price prediction for 2040 points to an average of $96.20 (low $55.50, high $176.05) — a potential gain of +125% on today's $42.83. Momentum favours further upside here.
In 2050, SPRB is projected to trade between $69.99 and $291.11, averaging $143.26 — a potential gain of +234% from today's $42.83. That is up +49% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SPRB today (≈ 23.34812 SPRB) could be worth
$3,344.91
+$2,344.91 (+234%) by 2050 · US Dollar
Based on the average projected SPRB price of $143.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SPRBwould be worth at today's price.
$1,000 invested in SPRB on Jul 31, 2025 (≈ 1.616162 SPRB) would be worth
$69.22
-$930.78 (-93.1%) today · 0.07× · US Dollar
Based on a SPRB entry price of $618.75 vs. today's $42.83.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $43.08 | $994.2 | -0.6% |
| 1 month ago | $52.54 | $815.11 | -18.5% |
| 3 months ago | $57.28 | $747.73 | -25.2% |
| 6 months ago | $77.99 | $549.17 | -45.1% |
| 1 year ago | $618.75 | $69.22 | -93.1% |
| All time (5.0y) ago | $48,262.5 | $0.89 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SPRB forecast.
Our base-case forecast reaches $86.00 around 2040.
Implied market cap at $86.00: $236.7M
The multi-year forecast depicts a bullish trajectory with meaningful upside over the longer term. In 2027, the average price is $51.48 with a 22.6% ROI and bullish sentiment, followed by 2028 with an average of $57.59 and 37.2% ROI, and 2029 with an average of $54.08 and 28.8% ROI.
By 2030, the average is $51.91 with a 23.6% ROI, and in 2031 the average is $51.26 with a 22.1% ROI. The trajectory continues with 2032 at $52.97 (26.1% ROI), 2033 at $68.89 (64.1% ROI), and 2034 at $70.26 (67.3% ROI), followed by 2035 at $65.15 (55.1% ROI).
The forecast climbs more decisively later, with 2040 averaging $92.06 (119.3% ROI) and 2050 averaging $137.48 (227.4% ROI), indicating substantial long-run upside despite near-term volatility and risks inherent in biotech equities.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $51.91, with a low of $36.72 and a high of $79.50. The corresponding ROI is 23.6%, and the sentiment is bullish.
Forecasts show positive ROI starting in 2027 (ROI 22.6%) and continuing through 2050 (ROI 227.4%). The sentiment is bullish in most years after 2026, though early years include neutral or modest gains.
Yes. The maximum forecasted prices include $113.06 in 2033, $117.51 in 2034, $168.53 in 2040, and $279.42 in 2050, indicating potential to surpass $100 in several years.
Current price is $41.99 and market cap is $115.57M. The asset is ranked #3954.
The near-term picture is bearish with RSI 30. The price is below the SMA50 of $50.20 and well below the SMA200 of $75.92. Support is at $41.99 and resistance at $55.88; the 30-day range is $33.42 to $52.76.
Spruce Biosciences, Inc. Community Discussion
0Share your Spruce Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.